Monday, August 22, 2011 (Last Updated: 08/23/2011)
MONDAY, Aug. 22 (HealthDay News) -- Nasal diffuse large B-cell lymphoma (DLBCL) has distinct clinical features and factors affecting prognosis, according to a study published online Aug. 11 in Cancer.
Ning-Ning Lu, M.D., from the Chinese Academy of Medical Sciences in Beijing, and colleagues described the clinical features and treatment outcomes of 25 patients with nasal DLBCL. All patients received combination chemotherapy with or without radiotherapy.
The investigators found that the patients with nasal DLBCL were predominantly male with early-stage disease and older than those without nasal DLBCL; they also had low-frequency B symptoms, elevated lactate dehyrogenase (LDH), good performance status, and low risk international prognostic index (IPI) scores. After initial treatment, the overall response rate, the three-year overall survival (OS) rate for the whole group, and the median OS time was 76 percent, 44 percent, and 35 months, respectively. IPI and performance status were significant prognostic factors for OS. Compared to the OS of 17 percent and median OS of 11 months for patients with IPI scores of two or three, respectively, the corresponding rates for patients with IPI scores of zero to one were significantly improved, at 54 percent and 52 months, respectively. Patients who achieved a complete response (CR) had a significantly better prognosis than those who did not achieve CR. The primary pattern of failure was extranodal spread.
"The current results indicated that primary nasal DLBCL appears to have distinct clinical features, its poor outcome and propensity for extranodal failure illustrate the need for innovative therapies," the authors write.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.